Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9661487 | 0.98 | ALDH1A1 (0.40) | ALDH1A1NPSR1 | |
| SCHEMBL23862434 | 0.83 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL523095 | 0.81 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL8757281 | 0.78 | ALDH1A1 (0.44) | ALDH1A1LMNANPSR1 | |
| SCHEMBL8776993 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL10244855 | 0.70 | ALDH1A1 (0.39) | ALDH1A1LMNANPSR1 | |
| SCHEMBL4631171 | 0.70 | ALDH1A1 (0.39) | ALDH1A1LMNANPSR1 | |
| SCHEMBL4413253 | 0.70 | ALDH1A1 (0.39) | ALDH1A1LMNANPSR1 | |
| SCHEMBL23767448 | 0.70 | ALDH1A1 (0.39) | ALDH1A1LMNANPSR1 | |
| SCHEMBL4405820 | 0.70 | ALDH1A1 (0.39) | ALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2788341-B1 | PROCESS FOR THE PREPARATION OF A THIOPRECURSOR FOR STATINS | DSM SINOCHEM PHARM NL BV (NL) | 2017-04-05 | — | — | EP | claimed |
| WO-2025021868-A1 | TRAF2 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2025-01-30 | — | — | WO | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-3438166-B1 | RESIN COMPOSITE FILM INCLUDING CELLULOSE MICROFIBER LAYER | ASAHI CHEMICAL IND (JP) | 2021-12-15 | — | — | EP | disclosed |
| US-20210353569-A1 | Analogs of CYP-Eicosanoids for Use in Treating or Preventing a Disorder Associated with Neovascularization and/or Inflammation | OMEICOS THERAPEUTICS GMBH (DE) | 2021-11-18 | — | — | US | disclosed |
| US-11174246-B2 | Direct AMPK activators | RIGEL PHARMACEUTICALS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3199701-B1 | THIN-FILM SHEET INCLUDING CELLULOSE FINE-FIBER LAYER | ASAHI CHEMICAL IND (JP) | 2021-10-27 | — | — | EP | disclosed |
| US-11130772-B2 | CYP-eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN | 2021-09-28 | — | — | US | disclosed |
| US-20080287371-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR MODULATION OF THE MIGRATING MOTOR COMPLEX | TRANZYME PHARMA INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080160452-A1 | Developer for light sensitive planographic printing plate material and manufacturing process of planographic printing plate employing the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20080160452-A1 | Developer for light sensitive planographic printing plate material and manufacturing process of planographic printing plate employing the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20070248910-A1 | heat resistant; low residual stress after curing; electronic insulation; semiconductor; a phthalic acid having an amine or imide group and an aromatic tetracarboxylic acid and a diamino siloxane or polysiloxane; tetracarboxybiphenyl; 5-aminoisophthalic acid; cured relief pattern; polyamide-imide precurso | ASAHI KASEI EMD CORPORATION (JP) | 2007-10-25 | — | — | US | disclosed |
| US-7282323-B2 | Highly heat-resistant, negative-type photosensitive resin composition | ASAHI KASEI EMD CORPORATION (JP) | 2007-10-16 | — | — | US | disclosed |
| EP-1775316-A1 | POLYAMIDE | Asahi Kasei EMD Corporation (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20050244739-A1 | Highly heat-resistant, negative-type photosensitive resin composition | ASAHI KASEI EMD CORPORATION (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1536286-A1 | HIGHLY HEAT-RESISTANT, NEGATIVE-TYPE PHOTOSENSITIVE RESIN COMPOSITION | Asahi Kasei EMD Corporation (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-5256523-A | Couplers for improved acutance, interimage effects; releasable development inhibitor, timing group | EASTMAN KODAK COMPANY (US) | 1993-10-26 | — | — | US | disclosed |
| US-3962232-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885LMNA 3544/4885NPSR1 2162/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885LMNA 3544/4885NPSR1 2162/4885 |
| US-11174246-B2 | Direct AMPK activators | PRKAA1, PRKAG1, PRKAB1 | ALDH1A1 490/4885LMNA 2265/4885NPSR1 2765/4885 |
| US-20210353569-A1 | Analogs of CYP-Eicosanoids for Use in Treating or Preventing a Disorder Associated with Neovascularization and/or Inflammation | ALOX5, ALOX15B, ALOX15 | ALDH1A1 274/4885LMNA 3403/4885NPSR1 1020/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | ALDH1A1 1152/4885LMNA 3544/4885NPSR1 2162/4885 |
| US-20080287371-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR MODULATION OF THE MIGRATING MOTOR COMPLEX | MLNR, CCKAR, CCKBR | ALDH1A1 4367/4885LMNA 4603/4885NPSR1 3633/4885 |
| US-11130772-B2 | CYP-eicosanoid derivatives | CYP4F3, CYP4A11, CYP1A2 | ALDH1A1 475/4885LMNA 2759/4885NPSR1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.